Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Equity Average (2016 - 2026)

Akebia Therapeutics has reported Equity Average over the past 10 years, most recently at $37.1 million for Q4 2025.

  • Quarterly Equity Average rose 174.51% to $37.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.1 million through Dec 2025, up 174.51% year-over-year, with the annual reading at -$8.3 million for FY2025, 79.22% up from the prior year.
  • Equity Average was $37.1 million for Q4 2025 at Akebia Therapeutics, up from $35.4 million in the prior quarter.
  • Over five years, Equity Average peaked at $229.1 million in Q1 2021 and troughed at -$49.8 million in Q4 2024.
  • The 5-year median for Equity Average is $16.8 million (2022), against an average of $32.6 million.
  • Year-over-year, Equity Average plummeted 618.97% in 2023 and then skyrocketed 188.19% in 2025.
  • A 5-year view of Equity Average shows it stood at $105.6 million in 2021, then crashed by 93.61% to $6.7 million in 2022, then plummeted by 618.97% to -$35.0 million in 2023, then tumbled by 42.26% to -$49.8 million in 2024, then skyrocketed by 174.51% to $37.1 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Equity Average are $37.1 million (Q4 2025), $35.4 million (Q3 2025), and $26.9 million (Q2 2025).